

University of Groningen

First do no harm

Hoekstra, Pieter J; Dietrich, Andrea

Published in:
European Child & Adolescent Psychiatry

DOI:
[10.1007/s00787-022-01950-7](https://doi.org/10.1007/s00787-022-01950-7)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Hoekstra, P. J., & Dietrich, A. (2022). First do no harm: use off-label antipsychotic medication in children and adolescents with great caution. *European Child & Adolescent Psychiatry*, 31(1), 1-3.
<https://doi.org/10.1007/s00787-022-01950-7>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



First do no harm: use off-label antipsychotic medication in children and adolescents with great caution

Pieter J. Hoekstra¹ · Andrea Dietrich¹

Published online: 22 January 2022

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022

In children and adolescents, antipsychotic medication is regularly prescribed on an off-label base, mostly for disruptive behavior or irritability. Especially in children, these medications have a range of side effects, of which weight gain is perhaps the most worrisome. In this issue of *European Child & Adolescent Psychiatry*, Pozzi and colleagues describe the results of a series of meta-analyses regarding increases in body weight, body mass index (BMI), and waist size associated with medium and long term use of different types of antipsychotics, based on data from observational studies [1]. The advantage of observational studies is that these more closely reflect the use in clinical practice than randomized controlled trials. The findings are really alarming. Six months use of olanzapine appeared to be associated with a BMI increase of 3.47 kg/m² (corresponding with a weight gain of almost 11 kg). Also, the more frequently used risperidone led to a substantial increase in BMI of 2 kg/m² (4.47 kg) after six months of treatment. While aripiprazole has a reputation of leading to less weight gain, still more than a year of treatment with aripiprazole was associated with an increase in BMI that was as high as 2.1 kg/m². Figures for increases in waist size are similarly alarming; e.g., six months of risperidone use was associated with an increase of 8.8 cm. Unfortunately, the observational data did not include Z values of the body measures. As there was no control group, receiving no treatment, Z values would have been of advantage, as they incorporate sex, age, and ethnicity factors and thus would have accounted for increases due to mere ageing. However, BMI-Z values (that are adjusted for age and sex) were available and indicated clear medication-associated increases of up to almost 1 standard deviation. The authors also conducted a meta-regression that

indicated that lower pre-treatment BMI was a risk factor for increases in BMI.

Another article in this issue addresses metabolic adverse events associated with the use of antipsychotics, by conducting a so-called sequence symmetry analysis, based on a medication prescription database covering a total of about 40 million young people aged 6–30 years from seven countries across Asia (Hong Kong, Japan, Korea, Taiwan and Thailand), Oceania (Australia), and Europe (Denmark) [2]. The study found that medicines that are used to treat dyslipidemia, hypertension, and hyperglycemia were 22% (95% CI 0–50%) more often prescribed after initiation of antipsychotics than before the start of such medication. This points to an association of antipsychotic medication use and metabolic adverse events. Of note, there was no difference between children and adolescents versus adults and also not between Asian and non-Asian ethnicity. Medications prescribed for dyslipidemia even increased by 51% (95% CI 18–93%). A strength of the study was the focus on apparently required prescribed medication for metabolic adverse events, highlighting the clinical significance of these metabolic events. The authors rightfully point to the importance of metabolic monitoring in all children and young adults who are treated with antipsychotics.

Occurrence of movement disorders is another well-known adverse event associated with the use of antipsychotics [3]. Perhaps less well known is that the risk of movement disorders is higher when risperidone is combined with methylphenidate [3], a combination that is widely used in clinical practice. The association between various antipsychotics and the development of seizures is also not widely known. The risk ratio of seizures is above 4, according to data from a nationwide database from South Korea from 2008 to 2018 [4]. Seizure risk was enhanced further with an increase in the number of antipsychotic drugs used. According to the authors, pediatric patients receiving antipsychotics, especially new or multiple antipsychotic users, should be carefully monitored for seizure development.

✉ Pieter J. Hoekstra
p.hoekstra@accare.nl

¹ Department of Child and Adolescent Psychiatry and Accare Child Study Center, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Despite the major health hazards associated with off-label antipsychotics use, we found that guideline recommendations regarding antipsychotic use in children and adolescents are often insufficiently met in clinical practice. This was our conclusion from an analysis of 436 medical records from 155 clinicians of 26 clinics within three Dutch child and adolescent psychiatry organizations [5]. The recommendation that antipsychotics should continuously be prescribed with concomitant psychosocial treatment was especially disregarded; in over half of the patients this was not the case. Also disappointing were our findings regarding consideration of contra-indications, with limited screening of medical risk factors in the patient and family history. Furthermore, there was insufficient education of the patient and the parents about antipsychotics, their effects, and lifestyle changes that may be needed.

It is unfortunate that the off-label use of antipsychotics in children and adolescents is rising in some parts of the world. For example, prescription data from a large Australian primary care database indicated a 62.8% increase of antipsychotics prescriptions from 2011 to 2018. The largest annual increase occurred in 10- to 14-year-olds, with the most frequently prescribed antipsychotics being risperidone (in youth < 15 years) and quetiapine (in 15- to 18-year-olds). In France, second-generation antipsychotic dispensing rates increased from 2.7 to 3.4 per 1,000 children and adolescents from 2006 to 2013. In contrast, according to US Medicaid prescription data, pediatric antipsychotic orders decreased from 54.9 prescriptions per 10,000 person months in the first quarter of 2013 to 34.1 per 10,000 person months in the last quarter of 2017 [6]. Also, antipsychotic prescriptions in Germany in children younger than 6 years decreased from 2.42 per 1000 subjects in 2004 to 0.48 in 2011 [7]. In the Netherlands, since a peak of 9.8 users per 1000 youths in 2009, prevalence rates stabilized, with declining dosages in milligram per kilogram from 2005 to 2015 [8].

Although risperidone is only licensed for the treatment of persistent aggression in conduct disorder in children and adolescents with subaverage intellectual functioning for a period of up to 6 weeks, the typical treatment duration in clinical practice is much longer. Finnish Prescription Registry data of all subjects aged 1–17 years who had started a second-generation antipsychotic drug (risperidone, quetiapine, aripiprazole, or olanzapine) between January 2008 and December 2016 revealed a mean and median treatment duration of 509 and 317 days, respectively [9]. The duration was shorter in girls than in boys ($p < 0.001$). Of all second-generation antipsychotic users, 16.0% used these longer than 600 days. In the Netherlands, the median duration of use was 6 months, with one in eight youths using antipsychotic drugs for 4 years or longer [8].

The notable side effects of antipsychotics are particularly concerning in light of their disappointing effects for treating

disruptive behaviors, especially on the long run. For example, the Treatment of Severe Childhood Aggression trial failed to identify long term (i.e., after 52 weeks) benefits of adding risperidone to parent training and stimulant medication for children with co-occurring attention-deficit/hyperactivity disorder (ADHD), disruptive behavior disorder, and serious physical aggression [10].

Recent findings suggest that alternative treatment strategies other than prescribing antipsychotics should be prioritized in clinical practice. That is, optimizing the dosing and adherence of stimulant medication and/or applying behavioral treatment may drastically reduce the need for antipsychotic medication for children with aggressive behaviors. This was suggested by a clinical trial directed at the effectiveness of risperidone or divalproex sodium as treatment for children with co-occurring ADHD, disruptive disorder, and significant aggressive behavior after insufficient response to systematically optimized stimulant treatment [11]. The trial failed to reach the target sample size due to the unexpected effectiveness of optimizing stimulant dosing and concurrent family-based behavioral treatment.

As an example of the potential of behavioral treatment, we recently showed substantial effects of home-based behavioral parent training for children with disruptive behavior problems who had not responded sufficiently to prior routine treatment (medication and/or clinic-based parent training) [12]. Compared to a waiting list, children allocated to home-based parent training improved significantly more regarding severity of disruptive behaviors, ADHD and oppositional defiant disorder symptoms, and internalizing problems.

In light of the available effectiveness and safety data, appropriate caution is required with regard to the off-label use of antipsychotics in children and adolescents. These should only be considered for short treatment durations, as a last resort in exceptional cases after behavioral treatments and stimulants have been optimized.

References

1. Pozzi M, Ferrentino RI, Scrinzi G, Scavone C, Capuano A, Radice S, Nobile M, Formisano P, Clementi E, Bravaccio C, Carnovale C, Pisano S (2022) Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression. *Eur Child Adolesc Psychiatry*. <https://doi.org/10.1007/s00787-020-01582-9>
2. Man KKC, Shao SC, Chaiyakunapruk N, Dilokthornsakul P, Kubota K, Li J, Ooba N, Pratt N, Pottgård A, Rasmussen L, Roughead EE, Shin JY, Su CC, Wong ICK, Kao Yang YH, Lai EC (2022) Metabolic events associated with the use of antipsychotics in children, adolescents and young adults: a multinational sequence symmetry study. *Eur Child Adolesc Psychiatry*. <https://doi.org/10.1007/s00787-020-01674-6>
3. Stämpfli D, Weiler S, Burden AM (2021) Movement disorders and use of risperidone and methylphenidate: a review of case reports

- and an analysis of the WHO database in pharmacovigilance. *Eur Child Adolesc Psychiatry* 30(7):1047–1058. <https://doi.org/10.1007/s00787-020-01589-2>
4. Jeon SM, Park S, Kim D (2021) Kwon JW (2021) Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case–control study in Korea. *Eur Child Adolesc Psychiatry* 30(3):391–399. <https://doi.org/10.1007/s00787-020-01525-4>
 5. Dinnissen M, Dietrich A, van der Molen JH, Verhallen AM, Buiteveld Y, Jongejan S, Troost PW, Buitelaar JK, Hoekstra PJ, van den Hoofdakker BJ (2020) Prescribing antipsychotics in child and adolescent psychiatry: guideline adherence. *Eur Child Adolesc Psychiatry* 29(12):1717–1727. <https://doi.org/10.1007/s00787-020-01488-6>
 6. Chavez LJ, Kelleher KJ, Beck A, Clarke GN, Penfold RB (2021) Trends over time in antipsychotic initiation at a large Children’s Health Care System. *J Child Adolesc Psychopharmacol* 31(5):381–386. <https://doi.org/10.1089/cap.2020.0190>
 7. Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, Riedel O (2017) Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011. *Eur Child Adolesc Psychiatry* 26(4):413–420. <https://doi.org/10.1007/s00787-016-0905-7>
 8. Kloosterboer SM, Schuiling-Veninga CCM, Bos JHJ, Kalverdijk LJ, Koch BCP, Dieleman GC, Hillegers MHJ, Dierckx B (2018) Antipsychotics in Dutch Youth: prevalence, dosages, and duration of use from 2005 to 2015. *J Child Adolesc Psychopharmacol* 28(3):173–179. <https://doi.org/10.1089/cap.2017.0155>
 9. Varimo E, Aronen ET, Mogk H, Rättö H, Saastamoinen LK (2021) Antipsychotic treatment duration in children and adolescents: a register-based nationwide study. *J Child Adolesc Psychopharmacol* 31(6):421–429. <https://doi.org/10.1089/cap.2020.0095>
 10. Gadow KD, Brown NV, Arnold LE, Buchan-Page KA, Bukstein OG, Butter E, Farmer CA, Findling RL, Kolko DJ, Molina BS, Rice RR Jr, Schneider J, Aman MG (2016) Severely aggressive children receiving stimulant medication versus stimulant and risperidone: 12-month follow-up of the TOSCA trial. *J Am Acad Child Adolesc Psychiatry* 55(6):469–478. <https://doi.org/10.1016/j.jaac.2016.03.014>
 11. Blader JC, Pliszka SR, Kafantaris V, Foley CA, Carlson GA, Crowell JA, Bailey BY, Sauder C, Daviss WB, Sinha C, Matthews TL, Margulies DM (2021) Stepped treatment for attention-deficit/hyperactivity disorder and aggressive behavior: a randomized, controlled trial of adjunctive risperidone, divalproex sodium, or placebo after stimulant medication optimization. *J Am Acad Child Adolesc Psychiatry* 60(2):236–251. <https://doi.org/10.1016/j.jaac.2019.12.009>
 12. Nobel E, Hoekstra PJ, Agnes Brunnekreef J, Messink-de Vries DEH, Fischer B, Emmelkamp PMG, van den Hoofdakker BJ (2020) Home-based parent training for school-aged children with attention-deficit/hyperactivity disorder and behavior problems with remaining impairing disruptive behaviors after routine treatment: a randomized controlled trial. *Eur Child Adolesc Psychiatry* 29(3):395–408. <https://doi.org/10.1007/s00787-019-01375-9>